NanoViricides, Inc. (NYSE American: NNVC) announced it has submitted an application to the Democratic Republic of Congo’s regulatory agency for approval to initiate a Phase II clinical trial evaluating its NV-387 Oral Gummies as a treatment for the ongoing Bundibugyo ebolavirus outbreak. The company has retained Om Sai Clinical Research Private Limited as the contract research organization for the study, with drug supplies already in the DRC.
NV-387 is an orally administered broad-spectrum antiviral designed to target host-side mechanisms that viruses rely on to infect cells, which the company believes may reduce the likelihood of viral resistance. The planned study builds on NanoViricides’ ongoing Phase II Mpox trial in the DRC and comes as the company seeks to address an outbreak that, according to the release, has resulted in more than 930 deaths and nearly 2,400 confirmed cases since May.
NanoViricides stated that NV-387’s oral formulation could offer logistical advantages over infusion-based therapies in resource-limited settings. If successful, the treatment could support development of a broad-spectrum therapy for Ebola and other filoviruses. The company’s lead drug candidate, NV-387, is also being developed for RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX and measles.
The company’s nanoviricide technology is based on intellectual property from TheraCour Pharma, Inc., and NanoViricides holds exclusive licenses for several antiviral applications. The company emphasized that the path to drug development is lengthy and requires substantial capital, and there can be no assurance that any of its candidates will show sufficient effectiveness for human clinical development.
For more information, see the full press release at https://ibn.fm/tmrCX and the company’s newsroom at https://ibn.fm/NNVC.
